Assembly Biosciences
Mr. Okazaki is Assembly’s Chief Executive Officer and President as well as a member of the Board. Mr. Okazaki joined Assembly in 2020 as its Chief Legal and Business Officer and was promoted to President and Chief Operating Officer. Prior to joining Assembly Bio, he served as Senior Vice President, Legal and Assistant Secretary at Gilead Sciences. During his 14-year career there, he built and led a global legal team supporting operations in the United States, Asia and Latin America, and advised on corporate governance and U.S. Securities and Exchange Commission (SEC) reporting matters. Over this period, he also led the structuring and legal execution efforts for Gilead’s acquisitions, divestitures and strategic collaborations. Prior to Gilead, he was an associate at Skadden, Arps, Slate, Meagher & Flom LLP in the law firm’s mergers and acquisitions and corporate finance practices. Mr. Okazaki earned a BA in Economics from Stanford University and a JD from the UC Hastings College of the Law.
This person is not in any offices
Assembly Biosciences
9 followers
Assembly Biosciences (NASDAQ: ASMB) is a clinical-stage biotechnology company committed to bringing finite and curative therapies to the 270 million people living with hepatitis B virus (HBV) worldwide. A pioneer in the development of a new class of potent, oral core inhibitor drug candidates, Assembly Bio’s approach aims to break the complex viral replication cycle of HBV to free patients from a lifetime of therapy. Assembly Bio’s strategy toward cure includes a leading portfolio of more potent, next-generation core inhibitors, proof-of-concept combination studies and a research program focused on the discovery of novel HBV targets.